精品文档---下载后可任意编辑乌司他丁联合多西他赛对乳腺癌免疫微环境的影响的开题报告Title：The impact of trametinib plus oubain on the immune microenvironment of breast cancerIntroduction：Breast cancer is one of the most common malignancies in women worldwide and carries a high morbidity and mortality rate. Although chemotherapy and endocrine therapy have been the major treatments for breast cancer, immunotherapy has shown promising results in recent years with the development of immune checkpoint inhibitors. However, most breast cancer patients are not responsive to immunotherapy due to the immunosuppressive microenvironment of tumors. Therefore, combination therapies are essential to overcome this limitation and improve the efficacy of immunotherapy.Methods：This study aims to investigate the impact of combining trametinib and ouabain on the immune microenvironment of breast cancer. The study will be a preclinical study using breast cancer cell lines and mouse models. The breast cancer cell lines, MDA-MB-231 and MCF-7, will be treated with trametinib and ouabain separately or in combination to evaluate their effects on cell proliferation, migration, and invasion. Moreover, the tumor-bearing mice will be divided into four groups: trametinib plus ouabain, trametinib alone, ouabain alone, and control. The tumors will be analyzed for their histology, microenvironmental changes, and immune infiltration.Results：The results of this study will demonstrate the potential of combining trametinib with ouabain in enhancing the immune microenvironment of breast cancer and improving the efficacy of immunotherapy.Conclusion：In conclusion, this study will provide preclinical evidence for the use of trametinib and ouabain as combination therapy to improve the immune microenvironment of breast cancer. This approach may lead to better clinical outcomes for breast cancer patients who are resistant to standard therapies or immunotherapy.
